These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 12084473)
1. Preferential targeting of apoptosis in tumor versus normal cells. Woynarowska BA; Woynarowski JM Biochim Biophys Acta; 2002 Jul; 1587(2-3):309-17. PubMed ID: 12084473 [TBL] [Abstract][Full Text] [Related]
2. DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells. Faivre S; Chan D; Salinas R; Woynarowska B; Woynarowski JM Biochem Pharmacol; 2003 Jul; 66(2):225-37. PubMed ID: 12826265 [TBL] [Abstract][Full Text] [Related]
3. Superior cytotoxicity and DNA cross-link induction by oxaliplatin versus cisplatin at lower cellular uptake in colorectal cancer cell lines. Virag P; Perde-Schrepler M; Fischer-Fodor E; Tatomir C; Dorneanu SA; Cernea VI; Irimie A Anticancer Drugs; 2012 Nov; 23(10):1032-8. PubMed ID: 22614106 [TBL] [Abstract][Full Text] [Related]
4. Apoptosis induction by the dual-action DNA- and protein-reactive antitumor drug irofulven is largely Bcl-2-independent. Herzig MC; Trevino AV; Liang H; Salinas R; Waters SJ; MacDonald JR; Woynarowska BA; Woynarowski JM Biochem Pharmacol; 2003 Feb; 65(4):503-13. PubMed ID: 12566077 [TBL] [Abstract][Full Text] [Related]
5. Reactivating p53 and Inducing Tumor Apoptosis (RITA) Enhances the Response of RITA-Sensitive Colorectal Cancer Cells to Chemotherapeutic Agents 5-Fluorouracil and Oxaliplatin. Wiegering A; Matthes N; Mühling B; Koospal M; Quenzer A; Peter S; Germer CT; Linnebacher M; Otto C Neoplasia; 2017 Apr; 19(4):301-309. PubMed ID: 28284059 [TBL] [Abstract][Full Text] [Related]
6. Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agents in the MV522 lung tumor model. Kelner MJ; McMorris TC; Rojas RJ; Estes LA; Suthipinijtham P Cancer Chemother Pharmacol; 2008 Dec; 63(1):19-26. PubMed ID: 18305940 [TBL] [Abstract][Full Text] [Related]
7. Proteomic profiling reveals DNA damage, nucleolar and ribosomal stress are the main responses to oxaliplatin treatment in cancer cells. Ozdian T; Holub D; Maceckova Z; Varanasi L; Rylova G; Rehulka J; Vaclavkova J; Slavik H; Moudry P; Znojek P; Stankova J; de Sanctis JB; Hajduch M; Dzubak P J Proteomics; 2017 Jun; 162():73-85. PubMed ID: 28478306 [TBL] [Abstract][Full Text] [Related]
8. Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells. Serova M; Calvo F; Lokiec F; Koeppel F; Poindessous V; Larsen AK; Laar ES; Waters SJ; Cvitkovic E; Raymond E Cancer Chemother Pharmacol; 2006 Apr; 57(4):491-9. PubMed ID: 16075278 [TBL] [Abstract][Full Text] [Related]
9. Cellular processing of platinum anticancer drugs. Wang D; Lippard SJ Nat Rev Drug Discov; 2005 Apr; 4(4):307-20. PubMed ID: 15789122 [TBL] [Abstract][Full Text] [Related]
10. Oxaliplatin triggers necrosis as well as apoptosis in gastric cancer SGC-7901 cells. Wu P; Zhu X; Jin W; Hao S; Liu Q; Zhang L Biochem Biophys Res Commun; 2015 May; 460(2):183-90. PubMed ID: 25767076 [TBL] [Abstract][Full Text] [Related]
11. Apoptotic and non-apoptotic cell death induced by cis and trans analogues of a novel ammine(cyclohexylamine)dihydroxodichloroplatinum(IV) complex. O'Neill CF; Ormerod MG; Robertson D; Titley JC; Cumber-Walsweer Y; Kelland LR Br J Cancer; 1996 Oct; 74(7):1037-45. PubMed ID: 8855971 [TBL] [Abstract][Full Text] [Related]
12. Copper-redox cycling by coumarin-di(2-picolyl)amine hybrid molecule leads to ROS-mediated DNA damage and apoptosis: A mechanism for cancer chemoprevention. Khan S; Zafar A; Naseem I Chem Biol Interact; 2018 Jun; 290():64-76. PubMed ID: 29803612 [TBL] [Abstract][Full Text] [Related]
13. Tumor-associated NADH oxidase (tNOX)-NAD+-sirtuin 1 axis contributes to oxaliplatin-induced apoptosis of gastric cancer cells. Chen HY; Cheng HL; Lee YH; Yuan TM; Chen SW; Lin YY; Chueh PJ Oncotarget; 2017 Feb; 8(9):15338-15348. PubMed ID: 28122359 [TBL] [Abstract][Full Text] [Related]
14. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin. Zeghari-Squalli N; Raymond E; Cvitkovic E; Goldwasser F Clin Cancer Res; 1999 May; 5(5):1189-96. PubMed ID: 10353756 [TBL] [Abstract][Full Text] [Related]
15. Development of resistance to a trinuclear platinum complex in ovarian carcinoma cells. Perego P; Gatti L; Righetti SC; Beretta GL; Carenini N; Corna E; Dal Bo L; Tinelli S; Colangelo D; Leone R; Apostoli P; Lombardi L; Beggiolin G; Piazzoni L; Zunino F Int J Cancer; 2003 Jul; 105(5):617-24. PubMed ID: 12740909 [TBL] [Abstract][Full Text] [Related]
16. Human Dkk-1, a gene encoding a Wnt antagonist, responds to DNA damage and its overexpression sensitizes brain tumor cells to apoptosis following alkylation damage of DNA. Shou J; Ali-Osman F; Multani AS; Pathak S; Fedi P; Srivenugopal KS Oncogene; 2002 Jan; 21(6):878-89. PubMed ID: 11840333 [TBL] [Abstract][Full Text] [Related]
17. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Vaisman A; Varchenko M; Umar A; Kunkel TA; Risinger JI; Barrett JC; Hamilton TC; Chaney SG Cancer Res; 1998 Aug; 58(16):3579-85. PubMed ID: 9721864 [TBL] [Abstract][Full Text] [Related]
18. Pro-oxidant milieu blunts scissors: insight into tumor progression, drug resistance, and novel druggable targets. Pervaiz S Curr Pharm Des; 2006; 12(34):4469-77. PubMed ID: 17168754 [TBL] [Abstract][Full Text] [Related]
19. Conjugation of platinum(IV) complexes with chlorambucil to overcome cisplatin resistance via a "joint action" mode toward DNA. Qin X; Fang L; Chen F; Gou S Eur J Med Chem; 2017 Sep; 137():167-175. PubMed ID: 28586717 [TBL] [Abstract][Full Text] [Related]
20. Cell cycle effects and induction of premitotic apoptosis by irofulven in synchronized cancer cells. Woynarowski JM; Woynarowska BA; Trevino AV; Salinas R; Herman TS; Waters SJ; Macdonald JR Cancer Biol Ther; 2004 Nov; 3(11):1137-42; discussion 1143-4. PubMed ID: 15467441 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]